Research mrsa partnering 2007 2012


Published on

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Research mrsa partnering 2007 2012

  1. 1. || Research|| MRSA Partnering 2007-2012 Aarkstore.comThe MRSA Partnering 2007-2012 report provides understanding and access to the MRSApartnering deals and agreements entered into by the worlds leading healthcare companies.Trends in MRSA partnering dealsTop MRSA deals by valueDeals listed by company A-Z, industry sector, stage of development, technology typeDescriptionThe MRSA Partnering 2007-2012 provides understanding and access to the MRSA partneringdeals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of MRSA partnering deals. The majority of deals are discoveryor development stage whereby the licensee obtains a right or an option right to license thelicensors MRSA technology. These deals tend to be multicomponent, starting with collaborativeR&D, and commercialization of outcomes.Understanding the flexibility of a prospective partner?s negotiated deals terms provides criticalinsight into the negotiation process in terms of what you can expect to achieve during thenegotiation of terms. Whilst many smaller companies will be seeking details of the paymentsclauses, the devil is in the detail in terms of how payments are triggered ? contract documentsprovide this insight where press releases do not.This data driven report contains over 50 links to online copies of actual MRSA deals andcontract documents as submitted to the Securities Exchange Commission by companies and theirpartners, where available. Contract documents provide the answers to numerous questions abouta prospective partner?s flexibility on a wide range of important issues, many of which will havea significant impact on each party?s ability to derive value from the deal.The initial chapters of this report provide an orientation of MRSA partnering trends.Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of thetrends in MRSA partnering since 2007, including a summary of deals by industry sector, stage ofdevelopment, deal type, and technology type. Numerous tables provide outline financial trends.Browse complete Report on :
  2. 2. NeelAarkstore EnterprisePhone:08149852585Email:enquiry@aarkstore.comURL:www.aarkstore.com Partnering Terms and AgreementsAnthrax Partnering 2007-2012E.coli Partnering 2007-2012MRSA Partnering 2007-2012Sepsis Partnering 2007-2012Common Cold Partnering 2007-2012Hepatitis Partnering 2007-2012Herper simplex Partnering 2007-2012HIV Partnering 2007-2012Influenza Partnering 2007-2012RSV Partnering 2007-2012Parasitic Partnering 2007-2012Fungal Partnering 2007-2012Tropical Disease Partnering 2007-2012Dengue Fever Partnering 2007-2012Malaria Partnering 2007-2012Renal Failure Partnering 2007-2012Dialysis Partnering 2007-2012Genitourinary Symptoms Partnering 2007-2012Chronic Kidney Disease Partnering 2007-2012Blood Substitute Partnering 2007-2012Anemia Partnering 2007-2012
  3. 3. Hemophilia Partnering 2007-2012Hypertension Partnering 2007-2012Hypercholesterolemia Partnering 2007-2012Congestive Heart Failure Partnering 2007-2012Coronary Artery Disease Partnering 2007-2012Atherosclerosis Partnering 2007-2012Arrhythmia Partnering 2007-2012Angina Partnering 2007-2012Abbott Partnering 2005-2012Actavis Partnering 2005-2012Alcon Partnering 2005-2012Allergan Partnering 2005-2012Amgen Partnering 2005-2012Apotex Partnering 2005-2012Astellas Partnering 2005-2012AstraZeneca Partnering 2005-2012Baxter Partnering 2005-2012Bayer Partnering 2005-2012Biogen Idec Partnering 2005-2012Boehringer Ingelheim Partnering 2005-2012Bristol-Myers Squibb Partnering 2005-2012Celgene Partnering 2005-2012Cephalon Partnering 2005-2012Chugai Partnering 2005-2012CSL Partnering 2005-2012Daiichi Sankyo Partnering 2005-2012Dainippon Sumitomo Partnering 2005-2012